dentoxol
Phase 2- Indications
- Radiation-induced oral mucositis
Company intelligence / Profile preview
Ingalfarma S.p.A.
Santiago / Providencia, Santiago Metropolitan Region, Chileingalfarma.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Ingalfarma S.p.A. develops and commercializes therapeutic solutions such as Dentoxol®, a mouthrinse for the prevention and treatment of oral mucositis. The company has conducted clinical studies on this product for use in patients with cancer therapy-induced oral mucositis. No detailed results from recent clinical trials are provided in the search results.
- Therapeutic areas
- Gastroenterology
- Modalities
- Mouthrinsesmall molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Ingalfarma S.p.A..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ingalfarma S.p.A..